Trials / Recruiting
RecruitingNCT06775912
Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Nanjing Bioheng Biotech Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is an open clinical pharmacological translational Research Study, aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RD06-05 in patients with active SLE, SSc, AAV, IIM, NMOSD, MS, MG
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RD06-05 CART Cell Injection | CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide |
Timeline
- Start date
- 2025-01-03
- Primary completion
- 2027-01-01
- Completion
- 2027-06-01
- First posted
- 2025-01-15
- Last updated
- 2026-02-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06775912. Inclusion in this directory is not an endorsement.